AstraZeneca starts to make modest profit from COVID-19 vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil prices extend losses as supply disruption fears ease
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
AstraZeneca (AZN) Has Supplied Two Billion Doses of COVID-19 Vaccine in 11 Months
November 16, 2021 6:00 AM ESTAstraZeneca (NASDAQ: AZN) and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.
This milestone comes just over 18 months after AstraZeneca and Oxford University formed their landmark partnership for the global development and distribution... More
AstraZeneca (AZN) Reports Positive Phase IIa Results from the EPICCURE Trial
November 15, 2021 8:24 AM ESTAstraZeneca (NASDAQ: AZN) announces positive Phase IIa results from the EPICCURE trial, demonstrating that AZD8601 met the primary endpoint of safety and tolerability in patients with heart failure.
In the trial, researchers injected mRNA encoding vascular endothelial growth factor (VEGF-A) known as AZD8601 directly into the myocardium of patients undergoing elective coronary artery bypass surgery (CABG) surgery. AZD8601 is being co-developed with Moderna.
In the study... More
